Bank of New York Mellon’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-17,528
| Closed | -$102K | – | 4471 |
|
|
2022
Q4 | $102K | Sell |
17,528
-102,732
| -85% | -$540K | ﹤0.01% | 4110 |
|
|
2022
Q3 | $806K | Sell |
120,260
-21,836
| -15% | -$132K | ﹤0.01% | 3309 |
|
|
2022
Q2 | $598K | Buy |
142,096
+124,206
| +694% | +$491K | ﹤0.01% | 3479 |
|
|
2022
Q1 | $60K | Buy |
17,890
+250
| +1% | +$793 | ﹤0.01% | 4496 |
|
|
2021
Q4 | $56K | Hold |
17,640
| – | – | ﹤0.01% | 4483 |
|
|
2021
Q3 | $58K | Hold |
17,640
| – | – | ﹤0.01% | 4414 |
|
|
2021
Q2 | $74K | Sell |
17,640
-89,549
| -84% | -$379K | ﹤0.01% | 4268 |
|
|
2021
Q1 | $535K | Buy |
107,189
+7,702
| +8% | +$62.2K | ﹤0.01% | 3653 |
|
|
2020
Q4 | $1.26M | Sell |
99,487
-2,888
| -3% | -$32.9K | ﹤0.01% | 3126 |
|
|
2020
Q3 | $1M | Sell |
102,375
-522
| -0.5% | -$5.14K | ﹤0.01% | 3121 |
|
|
2020
Q2 | $1.02M | Buy |
102,897
+2,039
| +2% | +$19.6K | ﹤0.01% | 3102 |
|
|
2020
Q1 | $892K | Buy |
100,858
+16,416
| +19% | +$162K | ﹤0.01% | 3066 |
|
|
2019
Q4 | $779K | Buy |
84,442
+947
| +1% | +$6.71K | ﹤0.01% | 3356 |
|
|
2019
Q3 | $491K | Sell |
83,495
-8,481
| -9% | -$90K | ﹤0.01% | 3546 |
|
|
2019
Q2 | $1.1M | Sell |
91,976
-14,303
| -13% | -$154K | ﹤0.01% | 3147 |
|
|
2019
Q1 | $1.28M | Buy |
106,279
+2,083
| +2% | +$30.7K | ﹤0.01% | 3018 |
|
|
2018
Q4 | $1.31M | Sell |
104,196
-76,584
| -42% | -$1.06M | ﹤0.01% | 2953 |
|
|
2018
Q3 | $2.68M | Buy |
180,780
+9,932
| +6% | +$156K | ﹤0.01% | 2692 |
|
|
2018
Q2 | $2.88M | Buy |
170,848
+13,204
| +8% | +$256K | ﹤0.01% | 2656 |
|
|
2018
Q1 | $3.61M | Sell |
157,644
-40,548
| -20% | -$902K | ﹤0.01% | 2509 |
|
|
2017
Q4 | $5.13M | Buy |
198,192
+70,468
| +55% | +$1.42M | ﹤0.01% | 2351 |
|
|
2017
Q3 | $1.88M | Buy |
127,724
+1,728
| +1% | +$25.1K | ﹤0.01% | 2874 |
|
|
2017
Q2 | $1.76M | Buy |
125,996
+1,852
| +1% | +$27.3K | ﹤0.01% | 2923 |
|
|
2017
Q1 | $2.12M | Buy |
124,144
+4,873
| +4% | +$58.4K | ﹤0.01% | 2816 |
|
|
2016
Q4 | $1.23M | Buy |
119,271
+7,860
| +7% | +$71.8K | ﹤0.01% | 3142 |
|
|
2016
Q3 | $1.13M | Sell |
111,411
-13,858
| -11% | -$151K | ﹤0.01% | 3109 |
|
|
2016
Q2 | $1.41M | Buy |
125,269
+2,661
| +2% | +$33.9K | ﹤0.01% | 2922 |
|
|
2016
Q1 | $1.68M | Sell |
122,608
-4,575
| -4% | -$65.8K | ﹤0.01% | 2756 |
|
|
2015
Q4 | $2.41M | Sell |
127,183
-107,022
| -46% | -$2.33M | ﹤0.01% | 2600 |
|
|
2015
Q3 | $4.4M | Sell |
234,205
-19,281
| -8% | -$328K | ﹤0.01% | 2310 |
|
|
2015
Q2 | $3.77M | Buy |
253,486
+121,505
| +92% | +$1.85M | ﹤0.01% | 2538 |
|
|
2015
Q1 | $2M | Sell |
131,981
-2,665
| -2% | -$37.2K | ﹤0.01% | 2866 |
|
|
2014
Q4 | $1.79M | Sell |
134,646
-38,236
| -22% | -$494K | ﹤0.01% | 2940 |
|
|
2014
Q3 | $2.18M | Buy |
172,882
+101,350
| +142% | +$983K | ﹤0.01% | 2820 |
|
|
2014
Q2 | $723K | Buy |
71,532
+55,316
| +341% | +$534K | ﹤0.01% | 3480 |
|
|
2014
Q1 | $218K | Buy |
+16,216
| New | +$229K | ﹤0.01% | 3826 |
|
Bank of New York Mellon's CNCE Position: Q1 2023 in Review
Bank of New York Mellon sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 17,528 shares — an estimated $102K sold.
Bank of New York Mellon first reported a position in CNCE in Q1 2014 and held it in 36 quarters. The position peaked at $5.13M in Q4 2017. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- Bank of New York Mellon reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Bank of New York Mellon sold 17,528 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $102K.
- Bank of New York Mellon first reported a position in Concert Pharmaceuticals, Inc. in Q1 2014 and held it in 36 quarters.
- Bank of New York Mellon's Concert Pharmaceuticals, Inc. position peaked at $5.13M in Q4 2017.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on Bank of New York Mellon's 13F filing for Q1 2023, filed 9 May 2023.